Donaustauf

Researchers are evaluating whether a preference-oriented quality of life QoL monitoring system with specific diagnostic and therapeutic options can improve the well-being of patients with lung cancer during routine follow-up care. This study builds on successful QoL interventions for breast and colorectal cancer and aims to adapt the system for lung cancer patients in multiple centers. The study uses electronic QoL questionnaires and links patient data with a cancer registry to support analysis. Participants are randomly assigned to one of two groups. The intervention group receives real-time results from an electronic QoL monitoring system based on the EORTC QLQ-C30 and QLQ-LC29 questionnaires, along with access to a multiprofessional network of therapists such as pain therapy, psychotherapy, social support, nutrition counseling, physiotherapy, fitness, respiratory therapy, and palliative care. The control group also completes QoL assessments but neither patients nor their physicians receive the results however, the therapist network is available for both groups. QoL is assessed at study entry and monthly for six months. Throughout the six-month follow-up, participants complete QoL questionnaires at baseline and monthly intervals. Researchers monitor the proportion of patients needing QoL therapy based on a profile with eight dimensions, with a focus on whether the intervention reduces this need after six months. Data collection includes linking clinical information from a cancer registry. The study involves multiple assessments, therapeutic referrals, and ongoing monitoring to evaluate quality of life improvements in lung cancer patients.

Researchers are evaluating the effects of a medicine called BI 1291583 in people aged 12 to under 18 and adults who have bronchiectasis, a lung condition that causes cough and sputum production. The study focuses on participants who have experienced flare-ups, or exacerbations, of their condition. It is a Phase III, randomized, double-blind, placebo-controlled trial designed to compare BI 1291583 with a placebo to understand its impact on bronchiectasis symptoms and flare-up frequency. Participants are randomly assigned to one of two groups one group takes BI 1291583 tablets and the other takes placebo tablets that look the same but contain no medicine. They take one tablet daily for up to 76 weeks about 1 year and 6 months. The study includes up to 10 clinic visits and around 13 phone calls over a total participation period of up to 1 year and 8 months. During the study, participants regularly use a smartphone diary to record their bronchiectasis symptoms, and study doctors monitor their health, noting any flare-ups and unwanted effects. The main outcome measured is the yearly rate of pulmonary exacerbations. Additional assessments include quality of life, lung function tests, and time to first severe exacerbation. Regular health checks ensure participant safety throughout the trial.